Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol.

Transforming growth factor-β activated kinase-1 (TAK1) is a member of the mitogen-activated protein kinase kinase kinase (MAP3K) family that regulates several signaling pathways including NF-κB signal transduction and p38 activation. TAK1 deregulation has been implicated in human diseases including cancer and inflammation. Here, we show that, in addition to its kinase activity, TAK1 has intrinsic ATPase activity, that (5Z)-7-Oxozeaenol irreversibly inhibits TAK1, and that sensitivity to (5Z)-7-Oxozeaenol inhibition in hematological cancer cell lines is NRAS mutation status and TAK1 pathway dependent. X-ray crystallographic and mass spectrometric studies showed that (5Z)-7-Oxozeaenol forms a covalent complex with TAK1. Detailed biochemical characterization revealed that (5Z)-7-Oxozeaenol inhibited both the kinase and the ATPase activity of TAK1 following a bi-phase kinetics, consistent with the irreversible inhibition mechanism. In DoHH2 cells, (5Z)-7-Oxozeaenol potently inhibited the p38 phosphorylation driven by TAK1, and the inhibition lasted over 6 h after withdrawal of (5Z)-7-Oxozeaenol. Profiling (5Z)-7-Oxozeaenol in a panel of hematological cancer cells showed that sensitive cell lines tended to carry NRAS mutations and that genes in TAK1 regulated pathways were enriched in sensitive cell lines. Taken together, we have elucidated the molecular mechanism of a TAK1 irreversible inhibitor and laid the foundation for designing next generation TAK1 irreversible inhibitors. The NRAS-TAK1-Wnt signaling network discerned in our study may prove to be useful in patient selection for TAK1 targeted agents in hematological cancers.

[1]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[2]  Hans Clevers,et al.  HDAC1 and HDAC2 Regulate Oligodendrocyte Differentiation By Disrupting β-Catenin-TCF Interaction , 2009, Nature Neuroscience.

[3]  Seiji Yoshimura,et al.  Role of a cysteine residue in the active site of ERK and the MAPKK family. , 2007, Biochemical and biophysical research communications.

[4]  J. Mizukami,et al.  TAK1-TAB1 fusion protein: a novel constitutively active mitogen-activated protein kinase kinase kinase that stimulates AP-1 and NF-kappaB signaling pathways. , 2002, Biochemical and biophysical research communications.

[5]  A. Wissner,et al.  The Development of HKI‐272 and Related Compounds for the Treatment of Cancer , 2008, Archiv der Pharmazie.

[6]  Jongdae Lee,et al.  TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide , 2000, Journal of leukocyte biology.

[7]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[8]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[9]  W N Hunter,et al.  Structure of trypanothione reductase from Crithidia fasciculata at 2.6 A resolution; enzyme-NADP interactions at 2.8 A resolution. , 1994, Acta crystallographica. Section D, Biological crystallography.

[10]  H. Sanjo,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[11]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[12]  Zhijian J. Chen,et al.  The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. , 2004, Molecular cell.

[13]  Sridhar Ramaswamy,et al.  RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis , 2012, Nature.

[14]  M. Su,et al.  Kinetic mechanism and ATP‐binding site reactivity of p38γ MAP kinase , 1999 .

[15]  R. Surabhi,et al.  TAK1 is Critical for IκB Kinase-mediated Activation of the NF-κB Pathway , 2003 .

[16]  J. Ninomiya-Tsuji,et al.  The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway , 1999, Nature.

[17]  Giulio Rastelli,et al.  Molecular modeling and crystal structure of ERK2-hypothemycin complexes. , 2008, Journal of structural biology.

[18]  R. Reid,et al.  Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Ninomiya-Tsuji,et al.  A Resorcylic Acid Lactone, 5Z-7-Oxozeaenol, Prevents Inflammation by Inhibiting the Catalytic Activity of TAK1 MAPK Kinase Kinase* , 2003, The Journal of Biological Chemistry.

[20]  Min Yu,et al.  TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers , 2012, Cell.

[21]  R. Copeland,et al.  An intrinsic ATPase activity of phospho-MEK-1 uncoupled from downstream ERK phosphorylation. , 2007, Archives of biochemistry and biophysics.

[22]  L. Honigberg,et al.  Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase , 2007, ChemMedChem.

[23]  K. Irie,et al.  Identification of a Member of the MAPKKK Family as a Potential Mediator of TGF-β Signal Transduction , 1995, Science.

[24]  R. Plummer,et al.  Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Allard Kaptein,et al.  Irreversible protein kinase inhibitors: balancing the benefits and risks. , 2012, Journal of medicinal chemistry.

[26]  A. Younes,et al.  Essential role of TAK1 in regulating mantle cell lymphoma survival. , 2012, Blood.

[27]  J. Pflugrath,et al.  The finer things in X-ray diffraction data collection. , 1999, Acta crystallographica. Section D, Biological crystallography.

[28]  G. Cheetham,et al.  Structural basis for the interaction of TAK1 kinase with its activating protein TAB1. , 2005, Journal of molecular biology.

[29]  S. Akira,et al.  Essential function for the kinase TAK1 in innate and adaptive immune responses , 2005, Nature Immunology.